TY - JOUR T1 - Quality of Life and Sexuality of Patients after Treatment for Gynaecological Malignancies: Results of a Prospective Study in 55 Patients JF - Anticancer Research JO - Anticancer Res SP - 5045 LP - 5049 VL - 32 IS - 11 AU - ADAK PILGER AU - ROLF RICHTER AU - CHRISTINA FOTOPOULOU AU - CARMEN BETETA AU - CHRISTINE KLAPP AU - JALID SEHOULI Y1 - 2012/11/01 UR - http://ar.iiarjournals.org/content/32/11/5045.abstract N2 - Aim: To assess the sexuality and quality of life (QoL) of women with gynaecological malignancies after multimodal therapy. Materials and Methods: This is a prospective analysis of the sexual status among women after treatment for gynaecological malignancies. Validated questionnaires-female sexual function index (FSFI-d), a semi-structured questionnaire and the quality of life score SF12, were applied. Results: Overall, 55 patients (median age=61, range=22-74 years) were enrolled. The cancer diagnoses were 54% ovarian, 26% breast, 13% cervical, 6% vulvar and 2% endometrial cancer. Twenty patients (55.6%) claimed experiencing changes in their sexuality after cancer treatment. The main reasons for this impairment were distorsion of their self image (45%; n=9), dry vaginal mucosa (25%; n=5), fear of physical harm (20%; n=4) and pain during sexual intercourse (20%; n=4). Forty percent of the patients gave no information about their sexuality after cancer therapy. Patients with cervical, endometrial or vulvar cancer had significantly higher changes in their sexuality compared to patients with ovarian cancer even after adjusting for age, recurrence rate and partnership status. The evaluation of SF12 revealed significantly higher psychological functional scores with increasing age. Patients who reported changes of their sexuality were also shown to have a lower overall SF12 score. Conclusion: Evaluation of sexuality and self image perception after cancer treatment is an unmet need and needs to be addressed in women with gynaecological malignancies. Further studies are warranted to assess the influence of the various types of cancer therapies in regard to their effect on sexuality and quality of life. ER -